Pipeline· June 2, 2026 · 10 min read
Orca-T allogeneic cell therapy PDUFA preview: access implications for AML, ALL, and MDS
By Ran Chen#PDUFA Date#FDA Approval#Hematology
Hematology therapies, oncology-adjacent access, evidence standards, buy-and-bill dynamics, and payer criteria.